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Cardiovascular hazards of hypertension
Hypertension is a highly prevalent, major, independent 
contributor to atherosclerotic cardiovascular disease. 
Hypertension imparts a two-to-threefold increased risk of 
cardiovascular events.1
The prevalence of hypertension is high (at least one in four 
adults), and it increases with age. In addition, hypertension 
has a rather large risk ratio, and these two factors contribute 
to the fact that approximately 35% of atherosclerotic 
cardiovascular events may be attributable to hypertension.1 
The relative risk of adverse events associated with 
hypertension is continuous and graded, and the absolute 
risk of adverse events depends on the degree of blood 
pressure elevation, and the presence of other cardiovascular 
risk factors.
From the Framingham data, the biennial age-adjusted rate 
per 1 000, for coronary disease due to hypertension, is 22.7 
for normotensives, and 45.4 for hypertension: a risk ratio 
of 2 for hypertension.2 Risk ratios are larger for stroke and 
heart failure, but coronary disease is much more common. 
Hypertension is only one of many risk factors causing 
atherosclerosis, and at least 80% of hypertensives have 
other risk factors. This compelling argument mandates 
that all hypertensives be tested for cholesterol (lipogram) 
and blood glucose, and also that that a history of smoking 
be noted.  Elevated cholesterol in hypertensives needs 
to receive a statin to reduce the number of myocardial 
infarctions, as shown in the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT), where there was a relative risk 
reduction of myocardial infarction of 36%.3
Smoking cessation is also important as hypertension, 
hypercholesterolemia and smoking, account for around 
85% of the cardiovascular risk for cardiovascular disease 
that can be modified.4
Compelling indications for specific drugs in this regard are 
post-myocardial infarction [angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin-specific receptor blockers 
(ARBs), beta blockers], angina (beta blockers, calcium-
channel blockers), heart failure (ACE inhibitors, ARBs, beta 
blockers, diuretics, aldosterone antagonists).5  
Left ventricular hypertrophy, measured on an 
electrocardiogram, chest X-ray, or echocardiography due 
to pressure overload, as well as multiple cardiovascular 
risk factors, may identify individuals who are more exposed 
to the adverse effects of high blood pressure. Regression 
of left ventricular hypertrophy with therapy significantly 
decreases cardiovascular risk.6
The measured level of systolic blood pressure is of critical 
significance, as increased systolic blood pressure is 
independently associated with an adverse, or increased, 
cardiovascular risk. The goal should be a systolic blood 
pressure of below 140 mmHg in everyone, including the 
elderly.7 It is also true that a reduction of systolic blood 
pressure of 20 mmHg can potentially halve cardiovascular 
risk. In people, usually the elderly, with isolated systolic 
hypertension (systolic blood pressure ≥ 140 mmHg, and 
diastolic blood pressure < 90 mmHg), those with a diastolic 
blood pressure of ≤ 70 mmHg or lower represent a category 
that has a higher risk, and is either untreatable or  difficult to 
treat. This is because it is possible to lower the already low 
diastolic blood pressure even further, to possible dangerous 
levels.8
What about age? The Blood Pressure Lowering Treatment 
Trialists Collaboration (BPLTTC) published a meta-analysis 
of 31 trials, of more than 190 000 randomised patients. 
They demonstrated that a reduction in blood pressure, 
using various antihypertensive drugs, was independent of 
the patient’s age.9 They also strongly advocated early and 
aggressive management of hypertension, irrespective of 
age. This analysis did not exclude the possibility that ACE 
inhibitors, and other renin system inhibitors, given as first-
line treatment in older people, might be less efficacious than 
diuretics, or calcium-channel blockers.4 Age should not 
exclude patients from treatment.
When diabetes mellitus occurs together with hypertension, 
the BPLTTC has shown similar benefit of treating 
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hypertension for hypertensives, with, or without, diabetes 
mellitus, using the major drug classes.10 Compelling 
indications for ACE inhibitors, ARBs, and other drugs, are 
made for hypertensive diabetics. In general, the goal of 
blood pressure reduction in diabetics should be < 130/80 
mmHg.
Patients with renal disease with an estimated creatinine 
clearance of < 60 ml/minute have significantly higher 
adjusted risk ratios for cardiovascular mortality and all-
cause mortality: risk ratio 1.80 (95% CI 1.33-2.44).6 
Microalbuminuria, a marker of impaired renal function, 
and also of a more generally endothelial dysfunction, is 
an established risk factor for cardiovascular morbidity 
and mortality, and for the development of end-stage 
renal disease in individuals with a high cardiovascular risk 
profile.6 A compelling indication for ACE-inhibitors or ARBs 
is made, although other drugs have also been shown to 
reduce albuminuria, such as aldosterone antagonists, 
dihydropyridine, calcium-channel blockers, and carvediol.5
General principles in hypertension 
treatment11
First-line treatment
Blood pressure lowering is the major driver of benefit of 
treatment, and the response to different classes of drugs 
is similar when compared head to head in heterogenous 
populations. However, individual responses to different 
classes can be significantly different. No antihypertensive 
drug has been found to be more effective than others in 
reducing all-cause mortality, or cardiovascular mortality. 
In broad terms, there is no difference between diuretics, 
calcium-channel blockers and inhibitors of the renin system, 
as optimal first-step treatment.  
Beta blockers may not be an optimal first-line agent. In 
general, people above the age of 55 years old, or those of 
black ethnic origin at any age, will generally have a greater 
blood pressure response with thiazide-type diuretics, or 
calcium-channel blockers. In young people, who have a 
more active renin-angiotensin system, inhibitors of the 
renin-angiotensin system will have a greater effect. Inhibitors 
of the renin-angiotensin system are also associated with a 
lower risk of the development of diabetes mellitus, a risk that 
can have a considerable impact in young people.
Initial combination treatment
Traditionally, combination treatment is used when 
monotherapy fails. However, for patients whose blood 
pressure is 20 mmHg or more above their systolic blood 
pressure goal (< 140 mmHg or < 130), the recommendation 
is to initiate combination therapy. The best combination 
is currently under debate, but an inhibitor of the renin-
angiotensin system, and a calcium-channel blocker, seems 
to be the preferred combination.
Combination therapy should also be initiated in high-risk 
hypertensives as early risk reduction is possible. This group 
of patients should also receive a statin, and very high-
risk patients with well-controlled hypertension, aspirin, 
as well. These high-risk individuals should be diagnosed 
(risk stratified) using global risk estimation, making use of 
risk charts such as Systematic Coronary Risk Evaluation 
(SCORE), or Framingham Risk Score.
Initial combination therapy is likely to become common 
practice. Would initial combination therapy not also solve 
the question of which drug to start with?
Resistant hypertension
Refractory hypertension is defined as blood pressure that 
is higher than target: 140/90 mmHg for most individuals, 
and 130/80 mmHg for those with diabetes or renal 
disease, despite the use of three different classes of 
antihypertensives that include a diuretic. Poor compliance 
should be excluded before embarking on expensive tests to 
search for a secondary cause of hypertension. Obstructive 
sleep apnoea is becoming an important co-morbidity that 
causes resistant hypertension. Primary hyperaldosteronism 
is another cause of resistant hypertension.
Lifestyle changes
Lifestyle modifications are effective in lowering blood 
pressure, and should be recommended to all patients 
with hypertension, even those on pharmacological drugs. 
Exercise, a higher intake of fruit and vegetables, a reduction 
in animal fat, moderation in alcoholic intake, and a reduction 
in salt intake, should be initiated in all patients.3
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